Skip to main content
TipRanks
Go Ultimate75% OFF

Zim Laboratories Ltd. (ZIMLAB) AI Stock Analysis

0 Followers
IN:ZIMLAB

Zim Laboratories Ltd.

(NSE:ZIMLAB)

Select Model
Rating:52.5Neutral
Price Target:INR 140.00▼(-5.50% Downside)
Action:reiterated
Date:08/21/26

The overall score is constrained by weak profitability and an extremely high valuation. The company's net income has fallen sharply, and the P/E ratio of 147.56 is a major red flag. Positive factors include a healthy balance sheet with low debt and moderately bullish technical momentum, with the stock trading above key moving averages. However, the negative free cash flow and declining margins are significant risks that outweigh these strengths.

Positive Factors
Diversified pharmaceutical platformZim Laboratories has a diversified pharmaceutical operating model spanning finished dosages, oral solid products and patient-friendly delivery formats. Its presence in both Indian and international markets, across branded and generic channels, supports multiple routes to sustained demand and reduces reliance on one market.
Negative Factors
Sharp profit deteriorationThe sharp fall in net income and operating profit signals meaningful pressure on current earnings power and operating efficiency. If weaker profitability persists, internally generated funds for product development, expansion and balance-sheet strengthening will be reduced, limiting the quality of growth.

Zim Laboratories Ltd. (ZIMLAB) vs. iShares MSCI India ETF (INDA)

-25%0%25%50%75%100%125%IN:ZIMLAB+102.72%INDA-4.06%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 7.98B
Dividend Yield
―
Average Volume (3M)
10.78K
Price to Earnings (P/E)
280.8
Beta (1Y)
0.81
Revenue Growth
13.14%
EPS Growth
-60.77%
Country
India
Employees
632
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Zim Laboratories Ltd. Business Overview & Revenue Model

Company Description

Established in 1984 and based in Nagpur, India, ZIM Laboratories Limited is a pharmaceutical company that develops, produces, and supplies both finished drug formulations and pre-formulation ingredients. Operating domestically and internationally, ZI...

Zim Laboratories Ltd. Financial Statement Overview

Summary

Financial performance is mixed. Revenue is stable but profitability has deteriorated sharply, with net margin falling to 1.6% and net income declining significantly. The balance sheet is healthy with low leverage, but return on equity is weak at 2.0%. Cash flow from operations is strong, but negative free cash flow due to high capex raises concerns about investment efficiency.

Income Statement

35Negative

Balance Sheet

70Positive

Cash Flow

45Neutral
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue4.14B3.69B3.74B3.68B3.99B3.31B
Gross Profit1.37B616.36M730.04M1.86B903.81M1.67B
EBITDA278.76M256.46M495.11M454.76M582.00M452.62M
Net Income20.71M58.38M121.65M172.46M244.34M145.50M
Balance Sheet
Total Assets5.48B5.39B4.72B4.47B3.42B3.42B
Cash, Cash Equivalents and Short-Term Investments225.94M278.02M20.37M96.41M64.66M34.20M
Total Debt1.51B1.26B1.18B1.12B620.00M533.14M
Total Liabilities2.55B2.43B2.20B2.08B1.41B1.66B
Stockholders Equity2.92B2.96B2.52B2.39B2.00B1.76B
Cash Flow
Free Cash Flow0-75.72M3.57M-576.45M15.00M339.81M
Operating Cash Flow0368.15M411.55M162.78M381.68M492.06M
Investing Cash Flow0-565.23M-399.27M-730.13M-362.04M-145.71M
Financing Cash Flow0410.81M-91.05M595.34M5.46M-329.70M

Zim Laboratories Ltd. Technical Analysis

Technical Analysis SentimentPositive
Last Price148.15

Price Trends

50DMA137.63Positive
100DMA128.31Positive
200DMA106.65Positive

Market Momentum

MACD1.26Negative
RSI59.05Neutral
STOCH52.28Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ZIMLAB, the sentiment is Positive. The current price of 148.15 is above the 20-day moving average (MA) of 136.51, above the 50-day MA of 137.63, and above the 200-day MA of 106.65, indicating a bullish trend. The MACD of 1.26 indicates Negative momentum. The RSI at 59.05 is Neutral, neither overbought nor oversold. The STOCH value of 52.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:ZIMLAB.

Zim Laboratories Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

IN:ZIMLAB against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:KILITCHIN:KILITCH65NeutralINR 8.20B33.95――13.87%-17.80%
IN:MEDICOIN:MEDICO63NeutralINR 1.57B11.40――50.78%20.08%
IN:VALIANTLABIN:VALIANTLAB59NeutralINR 5.50B32.43――102.37%176.45%
IN:ZIMLABIN:ZIMLAB53NeutralINR 7.95B280.79――13.14%-60.77%
IN:ALBERTDAVDIN:ALBERTDAVD52NeutralINR 4.30B14.99―0.66%19.69%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
IN:BAFNAPHIN:BAFNAPH46NeutralINR 11.35B98.66――8.74%31.20%

* Healthcare Sector Average

Performance Comparison

0%100%IN:ZIMLABIN:ALBERTDAVDIN:BAFNAPHIN:KILITCHIN:MEDICOIN:VALIANTLABDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:ZIMLAB and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:ZIMLABZim Laboratories Ltd.148.1574.66101.59%
IN:ALBERTDAVDAlbert David Ltd753.60-29.76-3.80%
IN:BAFNAPHBafna Pharmaceuticals Limited479.80312.35186.53%
IN:KILITCHKilitch Drugs (India) Limited234.6551.1327.86%
IN:MEDICOMedico Remedies Ltd.18.86-32.23-63.08%
IN:VALIANTLABValiant Laboratories Ltd.101.2028.2038.63%

Zim Laboratories Ltd. Corporate Events

Zim Laboratories’ CARE credit rating reaffirmed as outlook turns negative

Oct 8, 2026

Zim Laboratories Ltd. has disclosed that CARE Ratings has reaffirmed its credit ratings on the company’s bank facilities, signalling continued confidence from the rating agency in the firm’s credit profile. The long-term bank facilities of Rs 127.48...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 21, 2026